Hepatic enhancement during the hepatobiliary phase after gadoxetate disodium administration in patients with chronic liver disease: The role of laboratory factors

Journal of Magnetic Resonance Imaging

Volumn 34, Issue 2, 2011, Pages 301-309

  Chernyak, Victoria ^a   Kim, Jane ^a   Rozenblit, Alla M ^a   Mazzoriol, Fernanda ^a   Ricci, Zina ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

cirrhosis; gadoxetate disodium; liver imaging; parenchymal liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ECHOVIST; GADOXETIC ACID; LIVER PROTEIN;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHRONIC LIVER DISEASE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSION COEFFICIENT; FEMALE; HUMAN; LIVER FUNCTION TEST; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; END STAGE LIVER DISEASE; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 79960577313     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.22635     Document Type: Article

References (26)

1. Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY,. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 2010; 255: 459-466.
2. Seale MK, Catalano OA, Saini S, Hahn PF, Sahani DV,. Hepatobiliary- specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics 2009; 29: 1725-1748.
3. Cruite I, Schroeder M, Merkle EM, Sirlin CB,. Gadoxetate disodium-enhanced MRI of the liver: 2. Protocol optimization and lesion appearance in the cirrhotic liver. AJR Am J Roentgenol 2010; 195: 29-41.
4. Ringe KI, Husarik DB, Sirlin CB, Merkle EM,. Gadoxetate disodium-enhanced MRI of the liver: 1. Protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 2010; 195: 13-28.
5. Tajima T, Takao H, Akai H, et al. Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr 2010; 34: 362-366.
6. Tschirch FT, Struwe A, Petrowsky H, Kakales I, Marincek B, Weishaupt D,. Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol 2008; 18: 1577-1586.
7. Kim T, Murakami T, Hasuike Y, et al. Experimental hepatic dysfunction: evaluation by MRI with Gd-EOB-DTPA. J Magn Reson Imaging 1997; 7: 683-688. (Pubitemid 28365618)
8. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470. (Pubitemid 32119037)
9. Kamath PS, Kim WR,. The model for end-stage liver disease (MELD). Hepatology 2007; 45: 797-805. (Pubitemid 46450631)
10. Choi PC, Kim HJ, Choi WH, et al. Model for end-stage liver disease, model for end-stage liver disease-sodium and Child-Turcotte-Pugh scores over time for the prediction of complications of liver cirrhosis. Liver Int 2009; 29: 221-226.
11. Huo TI, Lee SD, Lin HC,. Selecting an optimal prognostic system for liver cirrhosis: the model for end-stage liver disease and beyond. Liver Int 2008; 28: 606-613.
12. Takao H, Akai H, Tajima T, et al. MR imaging of the biliary tract with Gd-EOB-DTPA: effect of liver function on signal intensity. Eur J Radiol 2011; 77: 325-329.
13. Ito K, Mitchell DG, Gabata T,. Enlargement of hilar periportal space: a sign of early cirrhosis at MR imaging. J Magn Reson Imaging 2000; 11: 136-140. (Pubitemid 30080966)
14. Dodd GD III, Baron RL, Oliver JH III, Federle MP,. Spectrum of imaging findings of the liver in end-stage cirrhosis. I. Gross morphology and diffuse abnormalities. AJR Am J Roentgenol 1999; 173: 1031-1036. (Pubitemid 29451308)
15. Awaya H, Mitchell DG, Kamishima T, Holland G, Ito K, Matsumoto T,. Cirrhosis: modified caudate-right lobe ratio. Radiology 2002; 224: 769-774. (Pubitemid 34919811)
16. Hanna RF, Aguirre DA, Kased N, Emery SC, Peterson MR, Sirlin CB,. Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features. Radiographics 2008; 28: 747-769.
17. Ito K, Mitchell DG, Gabata T, Hussain SM,. Expanded gallbladder fossa: simple MR imaging sign of cirrhosis. Radiology 1999; 211: 723-726. (Pubitemid 29249471)
18. Harbin WP, Robert NJ, Ferrucci JT Jr,. Diagnosis of cirrhosis based on regional changes in hepatic morphology: a radiological and pathological analysis. Radiology 1980; 135: 273-283. (Pubitemid 10105887)
19. Heidelbaugh JJ, Bruderly M,. Cirrhosis and chronic liver failure: I. Diagnosis and evaluation. Am Fam Physician 2006; 74: 756-762.
20. Ryeom H-K, Kim S-H, Kim J-Y, et al. Quantitative evaluation of liver function with MRI Using Gd-EOB-DTPA. Korean J Radiol 2004; 5: 231-239.
21. Motosugi U, Ichikawa T, Sou H, et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 2009; 30: 1042-1046.
22. Merkle EM, Dale BM, Paulson EK,. Abdominal MR imaging at 3T. Magn Reson Imaging Clin N Am 2006; 14: 17-26. (Pubitemid 43363395)
23. Nordenstedt H, White DL, El-Serag HB,. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010; 42: S206-S214.
24. Fattovich G, Stroffolini T, Zagni I, Donato F,. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-S50. (Pubitemid 39423368)
25. Willatt JM, Hussain HK, Adusumilli S, Marrero JA,. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008; 247: 311-330.
26. Leiner T, Kucharczyk W,. NSF prevention in clinical practice: summary of recommendations and guidelines in the United States, Canada, and Europe. J Magn Reson Imaging 2009; 30: 1357-1363.